Zenosense, Inc. (ZENO) Reports Successful Quantitative Testing Results for MIDS Cardiac™ Technology
Cardiovascular diseases are costing the U.S. $1 billion per day in medical fees and productivity losses The number of heart attacks is increasing on an annual basis, highlighting the importance of early detection technology Zenosense is developing a handheld device that could significantly lower cardiovascular-related death rate and associated medical costs by enabling swift, accurate diagnostic Health care technology company Zenosense, Inc. (OTC: ZENO) has announced the successful completion of a second round of testing for its MIDS Cardiac™ detection technology – a handheld system designed to rapidly test for certain cardiac biomarkers at the point of care, saving medical…